Clinical Trial: NCT03944772
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2025-01-30 |
Study Overview
Brief Summary
Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.
Official Title
A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy.
Conditions
Non-Small Cell Lung Cancer
Intervention / Treatment
- Drug: Osimertinib
- Drug: Savolitinib
- Drug: Gefitinib
- Drug: Necitumumab
- Drug: Durvalumab
- Drug: Carboplatin
- Drug: Pemetrexed
- Drug: Alectinib
- Drug: Selpercatinib
- Drug: Selumetinib
- Drug: Etoposide
- Drug: Cisplatin
- Drug: Datopotamab deruxtecan
Other Study ID Numbers
- D6186C00001
- 2023-504624-25-00
- 2018-003974-29
- 2018
- 2023
Start Date (Actual)
2019-06-25
Primary Completion Date (Estimated)
2025-05-06
Study Completion Date (Estimated)
2025-05-06
Enrollment (Actual)
247
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2025-01-30 |
Study Overview
Brief Summary
Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.
Official Title
A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy.
Conditions
Non-Small Cell Lung Cancer
Intervention / Treatment
- Drug: Osimertinib
- Drug: Savolitinib
- Drug: Gefitinib
- Drug: Necitumumab
- Drug: Durvalumab
- Drug: Carboplatin
- Drug: Pemetrexed
- Drug: Alectinib
- Drug: Selpercatinib
- Drug: Selumetinib
- Drug: Etoposide
- Drug: Cisplatin
- Drug: Datopotamab deruxtecan
Other Study ID Numbers
- D6186C00001
- 2023-504624-25-00
- 2018-003974-29
- 2018
- 2023
Start Date (Actual)
2019-06-25
Primary Completion Date (Estimated)
2025-05-06
Study Completion Date (Estimated)
2025-05-06
Enrollment (Actual)
247
Study Type
Interventional
Phase
Phase 2